Morningstar
•
Apr 30, 2026
Ionis Pharmaceuticals, Inc.: Ionis Earnings: Peak Sales Raised for Olezarsen Ahead of Label Expansion; Positive Long-Term Outlook
Summary
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Wayl
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Alnylam Pharmaceuticals, Inc.
May 01, 2026
•
ALNY
Analyst Report: Merck & Co., Inc.
May 01, 2026
•
MRK
Analyst Report: Incyte Corp
Apr 30, 2026
•
INCY
Market Update: NDAQ, HON, IEX, INCY, OMC, TMUS, TMO, BKR
Apr 30, 2026
•
TMUS, NDAQ, OMC, HON, TMO, BKR, INCY, IEX
Analyst Report: Incyte Corporation
Apr 29, 2026
•
INCY
